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Human transglutaminase 2 (TG2), a member of a large family of enzymes that catalyze protein crosslinking, plays an
important role in the extracellular matrix biology of many tissues and is implicated in the gluten-induced pathogenesis
of celiac sprue. Although vertebrate transglutaminases have been studied extensively, thus far all structurally
characterized members of this family have been crystallized in conformations with inaccessible active sites. We have
trapped human TG2 in complex with an inhibitor that mimics inflammatory gluten peptide substrates and have solved,
at 2-A ˚ resolution, its x-ray crystal structure. The inhibitor stabilizes TG2 in an extended conformation that is
dramatically different from earlier transglutaminase structures. The active site is exposed, revealing that catalysis
takes place in a tunnel, bridged by two tryptophan residues that separate acyl-donor from acyl-acceptor and stabilize
the tetrahedral reaction intermediates. Site-directed mutagenesis was used to investigate the acyl-acceptor side of the
tunnel, yielding mutants with a marked increase in preference for hydrolysis over transamidation. By providing the
ability to visualize this activated conformer, our results create a foundation for understanding the catalytic as well as
the non-catalytic roles of TG2 in biology, and for dissecting the process by which the autoantibody response to TG2 is
induced in celiac sprue patients.
Citation: Pinkas DM, Strop P, Brunger AT, Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5(12): e327. doi:10.1371/
journal.pbio.0050327
Introduction
Transglutaminases play important roles in diverse bio-
logical functions by selectively crosslinking proteins. They
catalyze, in a Ca
2þ-dependent manner, the transamidation of
glutamine residues to lysine residues, resulting in proteolyti-
cally resistant N
e(c-glutamyl)lysyl isopeptide bonds [1–3]. The
resulting crosslinked protein structures add strength to
tissues and increase their resistance to chemical and
proteolytic degradation. Among the members of this enzyme
family are factor XIIIa, the subunit of plasma transglutami-
nase that stabilizes ﬁbrin clots; keratinocyte transglutami-
nase, and epidermal transglutaminase, which crosslink
proteins on the outer surface of the squamous epithelium
[4]; and transglutaminase 2, the ubiquitous transglutaminase
that is the subject of our study.
Transglutaminase 2 (TG2, also known as tissue trans-
glutaminase) is structurally and mechanistically complex,
and has both intracellular and extracellular functions [1,5].
The catalytic mechanism, related to that of cysteine pro-
teases, involves an active site thiol that reacts with a
glutamine side chain of a protein or peptide substrate to
form a thioester intermediate from which the acyl group is
transferred to an amine substrate. In the absence of a suitable
amine, water can act as an alternative nucleophile, leading to
deamidation of the glutamine residue to glutamate (Figure 1)
[6]. Its catalytic activity requires millimolar Ca
2þ concen-
trations and is inhibited by guanine nucleotides. Thus,
intracellular TG2 lacks enzyme activity; instead, it functions
as a G-protein in the phospholipase C signal transduction
cascade [7]. Outside the cell, TG2 shapes the extracellular
matrix by binding tightly to both ﬁbronectin in the
extracellular matrix and integrins on the cell surface [8,9]
and promotes cell adhesion, motility, signaling, and differ-
entiation in a manner independent of its catalytic activity [9–
11]. Despite the variety of functions in which TG2 acts,
knockout mice are anatomically, developmentally, and
reproductively normal [12,13].
Although the x-ray crystal structures of several trans-
glutaminases (including human TG2) have been solved [14–
17], in each case the protein has been crystallized in a state in
which the active site is obscured. Here, we report the x-ray
crystal structure of human TG2 in a fundamentally novel
conformation with the active site exposed. Solving this
structure required stabilization of a transient state of a
gluten peptide–enzyme complex using a chemical biology
approach. Together with structure-based mutagenesis and
related biochemical experiments, the new TG2 structure
provides direct mechanistic insights into isopeptide bond
formation by TG2. As the prototypical x-ray crystal structure
of a catalytically activated transglutaminase, it also provides a
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biology, and evolution of this remarkable protein family, as
well as the role of TG2 in various pathogenic processes.
Results
Trapping a Transient Intermediate of TG2-Catalyzed
Transamidation
It has been suggested that TG2–gluten peptide complexes
play a role in the development of anti-TG2 autoantibodies in
the pathogenesis of celiac sprue, an autoimmune disorder
induced by the ingestion of gluten in genetically susceptible
individuals [18]. To investigate this hypothesis, we synthesized
a pentapeptide Ac-P(DON)LPF-NH2, where DON is the
electrophilic amino acid 6-diazo-5-oxo-L-norleucine (Figure
2). Its natural homolog PQLPY is found repeatedly in the
sequences of gluten proteins, where it undergoes TG2-
catalyzed deamidation prior to binding to the MHC class II
immune receptor human leukocyte antigen (HLA)-DQ2,
causing T cell proliferation in celiac sprue patients [18]. Ac-
P(DON)LPF-NH2 is an exceptionally high-afﬁnity irreversible
inhibitor of human TG2 with inhibition parameters Ki ¼ 60
nM and ki ¼ 0.5 min
 1. Its attachment to the active-site Cys
residue via a thioether linkage was veriﬁed by trypsinolysis
followed by LC/MS (unpublished data). The TG2-peptide
adduct is remarkably stable, which facilitated repuriﬁcation
and crystallization.
Structure of the TG2-Inhibitor Complex
Human TG2 consists of four domains: an N-terminal b-
sandwich (which, in contrast to previously solved TG2
structures, is fully resolved here) that binds to ﬁbronectin;
the catalytic domain containing a Cys-His-Asp catalytic triad;
and two C-terminal b-barrels belonging to the ﬁbronectin
Type III CATH superfamily [16]. However, in contrast to an
earlier structure, which showed human TG2 in a ‘‘closed’’
GDP-bound conformation (Figure 3A), the inhibitor-bound
structure is in an extended or ‘‘open’’ conformation (Figure
3B). When the N-terminal and catalytic domains of the two
structures are superimposed, the C-terminal residues are
displaced by as much as 120 A ˚ (Figure 3C). This remarkably
large conformational change is reminiscent of other multi-
domain proteins, including, for example, the inﬂuenza
hemagglutinin trimer, which undergoes a pH-dependent
conformational change [19]. The change in TG2 tertiary
structure is accompanied by changes in secondary structure
in the hinge region. For instance, a b-strand in the closed
structure consisting of residues Leu-312 to Arg-317 becomes
a-helical in the open structure, inducing backbone rearrange-
ments that extend to the active site.
The catalytic Cys (C277) is located in a hydrophobic tunnel
bridged by W241 and W332, which reside on separate loops in
the active site (Figure 4C). The inhibitor, which mimics the
acyl-donor substrate, occupies one side of the active-site
tunnel (Figure 4A). The other side of the tunnel is open
(Figure 4B) and presumably serves as the binding site for a
lysine residue or alternative nucleophilic substrate that
participates in the transamidation reaction. Notably, the
inhibitor ketone is hydrogen bonded to the indole of Trp-
241, as well as to the backbone amide of the catalytic cysteine
(Figure 4D), analogous to the hydrogen bonding arrangement
expected for oxyanion stabilization of acylation and deacy-
lation transition states.
The inhibitor forms an extended network of interactions
with the active site, including two hydrogen bonds between
TG2 and the peptide backbone, and hydrophobic interac-
tions with the Phe residue of the peptide (Figure 4D and 4E).
Additionally, the inhibitor exhibits good shape complemen-
tarity, burying more than 70% of its surface area upon
complex formation. The penultimate (Pro) residue of the
inhibitor assumes a trans conﬁguration and orients the
terminal Phe to bind in a deep hydrophobic pocket
consisting of residues A304, L312, I313, F316, I331, and
L420. Together, these features provide a clear structural basis
for the strong speciﬁcity of TG2 for QxP(hydrophobic)
signature sequences that are abundant in gluten peptides
[20–22].
Surprisingly, our structure reveals the existence of a vicinal
disulﬁde bond between two surface cysteine residues, C370
and C371 (Figure 5), which causes the intervening peptide
bond to assume a cis conﬁguration, distorting the peptide
backbone. It has been shown that TG2 can be inactivated by
the formation of a single intramolecular disulﬁde bond that
does not involve the active cysteine [23,24], and more
recently, that disulﬁde formation can interfere with the
ability of TG2 to adopt a compact conformation upon
incubation with GTP [25]. Because surface vicinal disulﬁdes
have been proposed to function as redox-activated conforma-
tional switches [26], it is possible that the C370–C371 disulﬁde
Figure 1. Reactions Catalyzed by TG2
TG2 can catalyze the transamidation of Gln to a suitable amine or the
deamidation of Gln to Glu.
doi:10.1371/journal.pbio.0050327.g001
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Author Summary
The transglutaminase family of enzymes is best known for
crosslinking proteins to form networks that strengthen tissues.
Although this enzyme family has been extensively studied, a
detailed understanding of the catalytic mechanism has been
hampered by the lack of a structure in which the enzyme is active.
We have solved, at atomic resolution, the structure of trans-
glutaminase 2 (TG2) in complex with a molecule that mimics a
natural substrate. The structure exposes the active site, giving direct
insights into the catalytic mechanism. Unexpectedly, we observed a
very large conformational change with respect to previous trans-
glutaminase structures. Very few proteins have been observed to
undergo this type of large-scale transformation. We propose a role
for this structural rearrangement in the early stages of celiac disease,
an autoimmune disorder in which TG2 is the principal autoantigen.
Besides the fundamental implications, our results should allow for
the rational design of better inhibitors of TG2 for pharmacological
and therapeutic purposes.bond underlies these redox features. In this context, we also
note that the motif (F/Y)CCGP associated with this disulﬁde is
conserved in TG1, TG2, TG4, TG5, and TG7, suggesting that
these transglutaminases may also be sensitive to changes in
redox potential.
Solution Conformation of TG2
To investigate the physiological relevance of the open form
of TG2 described above, we sought to characterize the closed
(GTP-bound) and open (inhibitor-bound) conformations of
TG2 in solution. We ﬁrst veriﬁed that both forms were
monomeric in solution, as determined by multi-angle laser
light scattering coupled to size exclusion chromatography
(SEC-MALLS; unpublished data). Next, we measured the radii
of hydration of inhibitor-bound and GTP-bound TG2 using
quasielastic light scattering and compared them to values
calculated from the representative crystal structures (Table 1)
[27]. In both cases, the measured values were within
experimental error of the calculated values, conﬁrming that
the conformation of inhibitor-bound TG2 in solution
resembles that observed in the crystal structure. Further-
more, the calculated radius of gyration of the inhibited TG2
matched a previous small-angle neutron scattering measure-
ment of Ca
2þ-activated TG2 [28]. Lastly, native gel electro-
phoresis revealed that the mobility of inhibited TG2 was
identical to that of nucleotide-free TG2 (Figure 6). Taken
together, these results suggest that the overall conformations
of nucleotide-free and Ca
2þ-activated TG2 in solution are
Figure 3. Overall Structures of GDP-Bound and Inhibitor-Bound TG2
The crystal structures are shown as ribbons, and simplified cartoons are included for clarity.
(A and B) The N-terminal b-sandwich is shown in blue (N), the catalytic domain (Core) in green, and the C-terminal b-barrels (b1 and b2) in yellow and
red, respectively. (A) GDP-bound TG2 [16]. (B) TG2 inhibited with the active-site inhibitor Ac-P(DON)LPF-NH2.
(C) The N-terminal b-sandwich and catalytic domains of the two structures are superimposed, highlighting the conformational change. The GDP-bound
structure is shown in blue and the inhibitor-bound structure in gold.
doi:10.1371/journal.pbio.0050327.g003
Figure 2. Inactivation of TG2 by a Reactive Gluten Peptide Mimic
(A) In the pathogenesis of celiac sprue, TG2 deamidates specific Gln residues in gluten peptides to Glu.
(B) The inhibitor Ac-P(DON)LPF-NH2 mimics a gluten peptide sequence that has high affinity for TG2. DON is the electrophilic amino acid 6-diazo-5-oxo
norleucine.
(C) The active-site Cys residue of TG2 nucleophilically attacks DON, resulting in a stable thioether adduct.
doi:10.1371/journal.pbio.0050327.g002
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An Activated Form of Transglutaminase 2Figure 4. The Active Site of TG2 and Enzyme–Inhibitor Interactions
(A) Electrostatic potential surface of TG2 (red indicates negative charge; blue, positive; contoured at 15 kBTt oþ15 kBT) in the vicinity of the peptide
inhibitor. (Carbon is indicated by cyan; nitrogen by blue; and oxygen by red.)
(B) Surface representation of the active-site tryptophan bridge. W332, W241, and inhibitor are shown in green, red, and cyan, respectively. The proposed
acyl-acceptor approach site is indicated.
(C) Stereo representation of the active site of TG2. The backbone of TG2 is shown as ribbons. The bridge tryptophans and a T360 that resides in front of
the proposed acyl-acceptor entrance are shown as sticks with semitransparent surfaces. It can be seen that the bridging tryptophan residues reside on
separate loops above the catalytic Cys (sulfur is indicated by yellow). The thioether attachment of the inhibitor (cyan indicates inhibitor carbons, and
gray indicates TG2 carbons) is also evident.
(D) Hydrogen-bonding interactions between TG2 and the peptide are shown as dashed lines.
(E) Schematic diagram of hydrophobic interactions between TG2 and the inhibitor.
doi:10.1371/journal.pbio.0050327.g004
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structure.
T360 Mutations Cause TG2 to Favor Deamidation over
Transamidation
Although our x-ray structure does not contain a bound
nucleophilic substrate, the observed active-site geometry and
steric constraints of protein transamidation suggest that the
acyl-acceptor approaches from the open side of the active-
site tunnel. T360, a residue that is conserved across all
catalytically active members of the transglutaminase family, is
located in front of the proposed acyl-acceptor tunnel
entrance. To investigate the role of this residue, T360A and
T360W mutants were generated by site-directed mutagenesis,
and kinetics for deamidation and transamidation were
measured. Although both activities were diminished, the
mutants showed an increase in preference for deamidation
with respect to transamidation compared to the wild-type
enzyme. Moreover, the T360A mutant strongly favored
deamidation, suggesting a possible role for this residue in
transamidation catalysis (Table 2). To verify the essential
catalytic role of the two tunnel-forming tryptophan residues,
we constructed W241A and W332A mutants, both of which
showed no detectable activity.
Discussion
Although conformational changes occur frequently in
enzymes, observations of large conformational changes such
as the one in this study are rare. Together, the x-ray crystal
structures of the closed and open forms of TG2 provide
fundamentally new insights into the biological dynamics of
this ubiquitous, multifunctional, and tightly regulated pro-
tein. Moreover, as the prototypical structure of a catalytically
activated transglutaminase, the crystal structure reported
here also yields clues regarding the regulation of enzymatic
activities of other members of the transglutaminase family.
Additionally, as TG2 is the principal autoantigen in celiac
sprue, the structure of human TG2 bound to a gluten peptide
mimetic presents an opportunity to dissect this autoimmune
response at a biochemical level.
TG2 Biology
Although ﬁbronectin crosslinking activity was the original
biological function assigned to TG2, more-recent data
suggest that the catalytically active form of mammalian
TG2 is a relatively rare species, both in the intracellular and
extracellular milieu. The absence of catalytic activity of
Figure 5. rA Weighted Electron Density Maps (2Fo-Fc) Contoured at 1r in the Vicinity of Cys-370 and Cys-371
(A) In the GDP-bound structure [16], Cys-370 and Cys-371 are reduced. (B) In the inhibitor-bound structure, the cysteine residues form a vicinal disulfide
bond, causing the intervening peptide bind to take on a cis configuration. (Carbon is indicated by grey, nitrogen by blue, oxygen by red, and sulfur by
yellow.)
doi:10.1371/journal.pbio.0050327.g005
Table 1. Measured Radii of Gyration and Hydration Are
Compared to Calculated Values from the Crystal Structures
Protein Complex Radius Measured Calculated
GDP-bound TG2 Rg 2.96 6 0.05 nm
a 2.93 nm
Rh 3.70 6 0.10 nm 3.67 nm
Ca
2þ-activated TG2 Rg 3.83 6 0.13 nm
a N/D
Inhibitor-bound TG2 Rg N/D 3.96 nm
Rh 4.10 6 0.10 nm 4.14 nm
aRadii of gyration were measured using small-angle neutron scattering by Casadio and
coworkers [28].
N/D, not determined; Rg, radius of gyration; Rh, radius of hydration.
doi:10.1371/journal.pbio.0050327.t001
Figure 6. Nondenaturing PAGE Conformation Study of Recombinant
Human TG2
TG2 was incubated with effectors, then subjected to electrophoresis.
Lane 1: TG2 incubated without effectors. As purified, this sample
assumes two conformational states. Extended dialysis of purified TG2
leads to virtual disappearance of the faster-migrating species, suggesting
that in the absence of both GTP and calcium, the protein adopts an
open-like conformation. Lane 2: incubation of TG2 with GTP and MgCl2,
allosteric inhibitors of the enzyme, increases the relative abundance of
the conformation with higher electrophoretic mobility. Lane 3:
incubation of TG2 with CaCl2, the enzyme activator, reduces the relative
abundance of the higher mobility conformer. The lower overall intensity
of this lane can be explained by oligomerization, as evidenced by
multiple bands of lower electrophoretic mobility (unpublished data).
Lane 4: active-site–inhibited TG2 incubated without effectors assumes a
conformation with the lower electrophoretic mobility. Lane 5: incubation
of active-site–inhibited TG2 with GTP and MgCl2 does not cause a shift in
mobility as it does for uninhibited TG2.
doi:10.1371/journal.pbio.0050327.g006
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of Ca
þ2 and GTP/GDP, and the demonstrated role of TG2 as a
G-protein inside the cell [1]. Consistent with these observa-
tions, the active site of GDP-bound TG2 is in a closed
conformation as a result of GDP binding between the ﬁrst b-
barrel domain and the catalytic domain (Figure S1). More
surprising, however, are recent observations that (1) extrac-
ellular TG2 is catalytically inactive under ordinary physio-
logical conditions (unpublished data), and (2) its ability to
promote cell adhesion, spreading, migration, or differentia-
tion is independent of catalytic activity [10,29]. The simplest
explanation for these observations is that, like intracellular
TG2, extracellular TG2 is also predominantly in a closed
conformation. We have observed that catalytically inactive
extracellular TG2 is transiently activated in response to
innate immune signals such as exposure to poly(I:C), a potent
ligand of the toll-like receptor TLR-3 (M. Siegel, P. Strnad, E.
Watts, K. Choi, B. Jabri, M. B. Omary, C. Khosla, unpublished
data). On the basis of these observations. we hypothesize that,
in a normal stress-free environment, most extracellular TG2
is maintained in the closed conformation as a result of
guanine nucleotide and/or integrin binding, despite relatively
high extracellular Ca
2þ concentrations. Physical or certain
forms of chemical injury trigger rapid activation of TG2 into
its catalytically active, open conformation.
Mechanism and Regulation of Transglutaminases
Nine members of the mammalian transglutaminase family
have been identiﬁed at the genetic level, seven of which have
been characterized at the protein level (transglutaminases 1–
5, factor XIIIa, and the catalytically inactive erythrocyte band
4.2). Although the regulation and substrate speciﬁcity varies
signiﬁcantly within this enzyme family, all active members
share a high degree of sequence similarity, including strict
conservation of key active-site residues such as the catalytic
triad, W241, W332, and T360. In our structure, the dual
hydrogen bonds between the inhibitor ketone and the indole
of W241 and the backbone amide of the catalytic Cys (Figure
4D) are consistent with a catalytic mechanism involving
oxyanion stabilization, a model that is supported by available
biochemical data [30]. Interestingly, early kinetic analysis of
both guinea pig liver TG2 and human factor XIIIa had led
Folk to propose the transient formation of a tunnel in the
active site during acylation [6]. Our results provide structural
support for this hypothesis. Speciﬁcally, we propose that the
bridging tryptophan residues and their corresponding loops
(Figure 4C) separate, analogous to a drawbridge, in order to
release the enzyme-bound transamidated product. On the
basis of these observations, we predict that an analogous
tunnel is also transiently formed between corresponding Trp
residues in other transglutaminases during their catalytic
cycle.
Notwithstanding their closely related catalytic mechanism,
the activity of individual transglutaminase members is
differentially regulated. For instance TG2, TG3, TG4, and
TG5 [31–33], but not TG1 or factor XIIIa [34], are inhibited
by GTP, and whereas TG3 requires cleavage at a loop between
the catalytic core and the C-terminal b-barrels for full display
of catalytic activity [35], cleavage at this loop leads to
inactivation of TG2 and factor XIIIa. Activation of factor
XIIIa is more intricate because the latent form is a
heterotetramer consisting of two catalytic A subunits (factor
XIIIa) and two regulatory B subunits. Activation involves
thrombin cleavage of an N-terminal peptide on the A
subunits, followed by dissociation of the tetrameric complex
and a concerted conformational change in factor XIIIa [1]. In
each case, a major conformational change such as that
observed for human TG2 in this study is required for
unmasking of the active-site residues and to allow access to
protein substrates for crosslinking.
Celiac Sprue Pathogenesis
The ability to visualize the structure of TG2 bound to a
high-afﬁnity gluten peptide analog has several potential
consequences for our understanding of gluten-induced
pathogenesis [36]. First, the atomic details of this covalent
complex may facilitate a deeper understanding of the
autoantibody response to TG2. If extracellular TG2 is
predominantly in a closed conformation, then the open
conformation described here is likely to expose self-epitopes
that are ordinarily inaccessible to the immune system. In
order for these ‘‘neo-epitopes’’ to trigger an autoantibody
response via a hapten carrier-like model in celiac sprue, TG2–
gluten adducts would have to be relatively stable. Enzymo-
logical analysis under conditions mimicking the gluten-fed
small intestine has veriﬁed the unusual stability of the TG2–
gluten peptide thioester adduct [20]. Thus, once extracellular
TG2 in the celiac small intestinal mucosa is activated, the
resulting TG2–gluten adducts may be sufﬁcient to trigger an
initial autoantibody response in HLA-DQ2–positive individ-
uals. The question of course arises, how is extracellular TG2
activated in the celiac mucosa? As mentioned above, at least
some innate immune signals, such as TLR-3 agonism, can
induce TG2 activation. The expression of TLR-2, 3, and 4i s
up-regulated in celiac mucosa, even in patients whose disease
is in remission [37]. We therefore hypothesize that, either TG2
Table 2. Kinetic Parameters of Wild-Type TG2, T360W, and T360A Mutants Using Ac-PQLPF-NH2 as the Acyl-Donor and Putrescine as
the Acyl-Acceptor
Transamidation Deamidation Transamidation/Deamidation
KM (mM) kcat (min
 1)k cat/KM (mM
 1min
 1)K M (mM) kcat (min
 1)k cat/KM (mM
 1min
 1)( k cat/KM)trans/(kcat/KM)de
WT 0.5 138 276 0.25 19 76 3.6
T360W N/D N/D 1.8 1.2 2.5 2.1 0.86
T360A N/D N/D 0.35 3.0 9.7 3.2 0.11
N/D, not determined; WT, wild type.
doi:10.1371/journal.pbio.0050327.t002
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in celiac mucosa, or more likely, gluten triggers extracellular
TG2 activation by interacting with certain up-regulated
innate immune receptors in celiac mucosa. Notably, recent
studies have suggested the occurrence of an innate immune
response to gluten in celiac sprue patients [38–41].
Last but not least, the availability of high-resolution
structures of both the GTP binding site and the active site
of human TG2 facilitates inhibitor design for this pharmaco-
logically signiﬁcant protein. In particular, two distinct classes
of pharmacological TG2 inhibitors are being explored: GTP
analogs [42,43], which presumably stabilize the closed con-
formation, and active-site inhibitors, which trap the open
conformation as shown in this study. Although both classes of
inhibitors block TG2 catalytic activity, we predict that they
will have different pharmacological effects. The ability to
visualize protein–ligand interactions at both ligand binding
sites should allow the rational design of inhibitors for
pharmacological and therapeutic purposes.
Materials and Methods
Synthesis of inhibitor. The peptide Ac-P(DON)LPF-NH2 was
synthesized using a modiﬁed method described for the synthesis of
similar products by Hausch et al. [44]. Brieﬂy, Ac-PELPF-NH2 was
synthesized via standard peptide synthesis techniques (Boc chemistry
on 4-methylbenzhydryl amine resin). The N-terminus was acetylated
using acetic anhydride (Sigma) on the resin, and the peptide was
cleaved with triﬂic acid (Sigma). The resulting crude peptide was
dried over potassium hydroxide in vacuo for several days. A total of
30 mg of crude peptide was dissolved in 4 ml of anhydrous THF
(Acros); 1.6 equivalents N-methyl morpholine (Sigma) was added,
followed by the dropwise addition of 1.2 equivalents iBu-COOCl
(Sigma) on ice. The mixture was allowed to react for 5 min.
Diazomethane was generated in situ by adding 1 M potassium
hydroxide to a suspension of N-methyl-N-nitroso-p-toluenesulfona-
mide (Diazald; Sigma) in ethanol on ice. The evolved diazomethane
was passed through a cannula and collected in 20 ml of extra-dry
ether (Acros), using nitrogen as a carrier gas. The reaction mixture
was added dropwise to the diazomethane solution and allowed to
react for 30 min on ice, followed by 30 min at room temperature. The
solvent was removed in vacuo, and the crude product was puriﬁed by
C18 reverse-phase high performance liquid chromatography (HPLC)
using a gradient of water þ 0.1 M triethylamine bicarbonate (Fluka)
and acetotnitrileþ0.1 M triethylamine bicarbonate. The product was
v e r i ﬁ e db yl i q u i dc h r o m a t o g r a p h y–mass spectrometry (LC/MS)
(MþH)
þ¼ 667.3, and a yield of 17% quantiﬁed by UV275 absorbance.
Protein expression and puriﬁcation. Site-directed mutagenesis of
TG2 was performed using QuickChange mutagenesis (Stratagene)
protocols and veriﬁed by sequencing. N-terminally His6-tagged wild-
type and mutant human TG2 were expressed and puriﬁed as
described in Piper et al. [20] with the minor modiﬁcation that
mutant proteins were induced at 13 8C.
Preparative inhibition of TG2 by Ac-P(DON)LPF-NH2. For large-
scale preparation of inhibited TG2 for crystallization, freshly
prepared TG2 (5 mg, no glycerol) was incubated in 3 ml of reaction
buffer (20 mM Tris-HCl, 1 mM DTT, 1 mM EDTA, 150 mM NaCl [pH
7.2], and 10 mM CaCl2) with 2-mg Ac-P(DON)LPF-NH2 at room
temperature for 30 min and then at 4 8C overnight. The protein was
repuriﬁed by anion exchange chromatography, buffer exchanged, and
concentrated as described for uninhibited TG2 [20]. Alternatively,
lower concentrations of TG2 were used in the reaction buffer prior to
anion exchange in some preparations. At higher concentrations of
TG2, the protein precipitated from solution but subsequently
redissolved upon dilution in anion exchange buffer. Each preparation
yielded good-quality crystals, indicating that the protein was not
denatured after the precipitation/redissolution process.
Crystallization, data collection, and reﬁnement. Crystals of the
TG2–inhibitor adduct were grown by the hanging-drop method at 25
8C using freshly prepared inhibited TG2 at 10 mg/ml with an equal
volume of a precipitant buffer containing 100 mM HEPES (pH 7.25)
and 1.25 M ammonium sulfate. Football-shaped crystals appeared in a
few days and grew to about 150 lm 3 150 lm 3 300 lm in 1 wk.
Crystals were soaked stepwise in mother liquor supplemented with
10%–20% glycerol and then ﬂash frozen in liquid nitrogen.
Diffraction data were collected at Advanced Light Source on
beamline 8.3.1 and at Stanford Synchrotron Radiation Laboratory
on beamline 11–1. The crystals belong to the space group P41212 with
unit cell dimensions a¼71.7 A ˚ ,b¼71.7 A ˚ ,c¼309.2 A ˚ . All data were
processed with DENZO and SCALEPACK [45].
The structure was solved by molecular replacement using human
transglutaminase 2 structure (Protein Data Bank PDB code 1KV3) as
a starting model. Although a molecular replacement solution was
found using this structure, the b-barrel domains were clashing with
symmetry-related mates. It was apparent that the inhibited TG2
undergoes large conformational change. The 1KV3 structure was
therefore separated into four domains, which were searched
independently in PHASER [46]. After the N-terminal and catalytic
domains were located, their positions and orientations were reﬁned
in CNS. The positions and orientations of the two remaining b-
barrels were sequentially located with PHASER, using ﬁxed N-
terminal and catalytic domains.
Alternate cycles of manual model building using the program O
[47] and COOT [48]; positional and individual B-factor reﬁnement
with the program CNS [49] and REFMAC [50]; and addition of the
inhibitor, water molecules, and sulfates to the model reduced the R
and R-free to 22.8% and 26.6%, respectively, for all of the reﬂections
(2.0-A ˚ resolution). A total of 89.8% of the residues in TG2 are in the
most favored regions of the Ramachandran plot, and 10.2% are in the
additional allowed regions as calculated with PROCHECK [51]. The
ﬁnal model contains 5,522 atoms (5,188 protein, 47 ligand, 25 ion, and
262 waters) (Table S1). Residues 307–308, 319–327, 407–413, 462–471,
and 684–687 are disordered in the structure and could not be built.
SEC-MALLS. A DAWN EOS (Wyatt Technology) with a K5 ﬂow cell
and a 690-nm wavelength laser was used in the light scattering
experiments. Refractive index measurements were performed using
an OPTILAB DSP instrument (Wyatt Technology) with a P10 cell. A
value of 0.185 ml/g was assumed for the dn/dc ratio of the protein.
Samples at approximately 3 mg/ml were passed over a Shodex-804
size exclusion column at 0.5 ml/min. Monomeric bovine serum
albumin was used to normalize the detector responses. Astra software
(Wyatt Technology) was used to analyze the light scattering data.
Hydrodynamic radii were calculated with HYDROPRO [27].
Kinetics. The kinetic parameters of deamidation, transamidation,
and inhibition were determined using a coupled enzyme assay and
methods previously described [20,44,52]. Transamidation kinetics
experiments were performed using 3 mM putresceine and varying
glutamine donor concentrations.
Native PAGE. Native gel electrophoresis experiments were
performed using a method similar to those previously described
[25,53]. Brieﬂy, TG2 or inhibited TG2 (2.5 lM) was incubated for 1 h
at room temperature in preincubation buffer (75 mM imidazole, 0.5
mM EDTA, 5 mM DTT [pH 7.2]) with or without 500 lM GTP/1mM
MgCl2 or 5 mM CaCl2. Laemmli native buffer was added, and 1.5 lgo f
protein was loaded onto a 4%–20% Tris-HCl ReadyGel (Bio-Rad)
using Tris-glycine as the running buffer. For 75 min, 125 V was
applied at 4 8C. The gel was stained with SimplyBlue SafeStain
(Invitrogen) and destained with water.
Supporting Information
Figure S1. Overlay of the Active Sites of TG2 in the GDP-Bound and
Inhibitor-Bound Structures
The inhibitor-bound structure of TG2 is shown in grey with the
inhibitor in cyan. The equivalent in the GDP-bound structure is
shown in blue. In the GDP-bound structure, the acyl-donor site is
occupied by Y516, a residue located on a loop on b-barrel 1 (magenta)
which is remote in the inhibitor-bound structure. The entire active
site is buried by this b-barrel in the GDP-bound structure.
Found at doi:10.1371/journal.pbio.0050327.sg001 (2.0 MB TIF).
Table S1. Reﬁnement and Model Statistics
Found at doi:10.1371/journal.pbio.0050327.st001 (25 KB DOC).
Accession Numbers
The Protein Data Bank (PDB; http://www.rcsb.org/pdb) accession
number/PDB ID for the GDP-bound human transglutaminase is
1KV3. Coordinates for human transglutaminase 2 inhibited with the
active-site inhibitor Ac-P(DON)LPF-NH2 have been deposited in the
Protein Data Bank under accession number 2Q3Z.
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